Pharmacologic therapy for diabetic retinopathy

Bibliography

• KLEIN R: The epidemiology of diabetic eye disease. In: Textbook of diabetes. Pickup J & Williams G (Eds) Blackwell Science, Oxford (1997):44.1–44.9.
   Google Scholar
• D'AMICO DJ: Diseases of the retina. N Engl. J. Med. (1994) 331:95–106.
   PubMed Web of Science ®Google Scholar
• BARRY P: The management of diabetic eye disease. In: Textbook of diabetes. Pickup J & Williams G (Eds) Blackwell Science, Oxford (1997):47.41–47.42.
   Google Scholar
• FINE SL, PATZ A: Ten years after the Diabetic Retinopathy Study. Surv. Oplathalmol (1987) 94:739–740.
   Google Scholar
• KLEIN R, KLEIN BE, MOSS SE, CRUICKSHANKS KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV: the long-term incidence of macular edema. Ophthalmology (1995) 102:7–16.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Photocoagulation for diabetic macular edema; early treatment diabetic retinopathy study report number 1. Early Treatment of Diabetic Retinopathy Study Group. Arch. Oplathalmol (1985) 103:1796–1806.
   PubMed Web of Science ®Google Scholar
• ANTONELLI-ORLIDGE A, SMITH S, DAM ORE P: Influence of pericytes on capillary endothelial cell growth. Am. Rev. Respir. Dis. (1989) 140:1129–1131.
   PubMed Web of Science ®Google Scholar
• CAMPOCHIARO PA: Retinal and choroidal neovascularization. J. Cell Physiol (2000) 184:301–310.
   PubMed Web of Science ®Google Scholar
• ••An excellent in-depth review ofangiogenesis mechanisms and some therapeutic options.
   Google Scholar
• NO AUTHORS LISTED: Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Diabetic Retinopathy Study Group. Surv. Oplathalmol (1978) 85:82–106.
   PubMed Web of Science ®Google Scholar
• •A classic report of the DRS.
   Google Scholar
• NO AUTHORS LISTED: Proliferative diabetic retinopathy: treatment with xenon-arc photocoagulation. Interim report of multicentre randomized controlled trial. British Multicentre Trial of Photocoagulation. Br. Med. J. (1977) 1:739–741.
   PubMed Web of Science ®Google Scholar
• SMIDDY WE: Vitrectomy for complications of diabetic retinopathy. hat. Oplathalmol Clin. (1998) 38:155–167.
   PubMedGoogle Scholar
• FERRIS FL: How effective are treatments for diabetic retinopathy? JAMA (1993) 269:1290–1291.
   PubMed Web of Science ®Google Scholar
• ••An outline of epidemiological aspects andlaser treatment of diabetic retinopathy with respect to societal costs.
   Google Scholar
• MUKAMEL DB, BRESNICK GH, WANG Q, DICKEY CF: Barriers to compliance with screening guidelines for diabetic retinopathy. Ophthalmic Epidemiol (1999) 6:61–72.
   PubMedGoogle Scholar
• NO AUTHORS LISTED: Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic retinopathy study report no. 5.Diabetic Retinopathy Study Group. Dev. Oplathalmol (1981) 2:248–261.
   PubMed Web of Science ®Google Scholar
• COLWELL JA: Intensive insulin therapy in Type II diabetes: rationale and collaborative clinical trial results. Diabetes (1996) 45\(Suppl. 3):587–590.
   PubMedGoogle Scholar
• •Good overview of clinical trials of glycaemic control.
   Google Scholar
• TURNER RC: The UK Prospective diabetes study. A review. Diabetes Care (1998) 21\(Suppl. 3):C35–C38.
   PubMedGoogle Scholar
• NO AUTHRS LISTED: The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Diabetes Complications And Control Trial Study Group. Arch. Oplathalmol (1995) 113:36–51.
   PubMed Web of Science ®Google Scholar
• ENGERMAN RL, KERN T: Progression of incipient diabetic retinopathy during good glycemic control. Diabetes (1987) 36:808–812.
   PubMed Web of Science ®Google Scholar
• •A classic animal study elucidating some aspects of the pathophysiology of diabetic retinopathy.
   Google Scholar
• NO AUTHORS LISTED: Early worsening of diabetic retinopathy in the diabetes control and complications trial. The Diabetes Control And Complications Trial Research Group. Arch. Oplathalmol (1998) 116:874–886.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38.UK Prospective Diabetes Study Group. Br. Med. J. (1998) 317:703–713.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes. UKPDS 39.UK Prospective Diabetes Study Group. Br. Med. J. (1998) 317:713–720.
   PubMed Web of Science ®Google Scholar
• DANSER AHJ, VAN DEN DORPEL MA,DEINUM J et al: Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. Clin. Endocrinol Metab. (1989) 68:160–167.
   Google Scholar
• DANSER AHJ, DERKX FH, ADMIRAAL PJ et al: Angiotensin levels in the eye. Invest. Oplathalmol Vis. Sci. (1994) 35:1008–1018.
   PubMed Web of Science ®Google Scholar
• FUNATSU H, YAMASHITA H, IKEDA T, NAKANISHI Y, KITANO S, HORI S: Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am. J. Ophthalmol (2002) 133:537–543.
   PubMed Web of Science ®Google Scholar
• HOGEBOOM VAN BUGGENUM IM, POLAK BC, REICHERT-THOEN JW, DE VRIES-KNOPPERT WA, VAN HINSBERGH VW, TANGELDER GJ: Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia (2002) 45:203–209.
   PubMed Web of Science ®Google Scholar
• CHATURVEDI N, FULLER JH, POKRAS F, ROTTIERS R, PAPAZOGLOU N, AIELLO LP: Circulating plasma vascular endothelial growth factor and microvascular complications of Type 1 diabetes mellitus: the influence of ACE inhibition. Euclid Study Group. Diabet. Med. (2001) 18:288–294.
   PubMed Web of Science ®Google Scholar
• NAGISA Y, SHINTANI A, NAKAGAWA S: The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetalogia (2001) 44:883–888.
   PubMed Web of Science ®Google Scholar
• CHATURVEDI N, SJOELIE AK, SVENSSON A: The diabetic retinopathy candesartan trials (DIRECT) programme, rationale and study design. The Direct Programme Study Group. Renin Angiotensin Aldosterone Syst. (2002) 3:255–261.
   PubMed Web of Science ®Google Scholar
• KINOSHITA JH: Aldose reductase in the diabetic eye. XLIII Edward Jackson memorial lecture. Am. J. Oplathalmol (1986) 102:685–692.
   PubMed Web of Science ®Google Scholar
• ROBISON W: Prevention of diabetes-related retinal microangiopathy with aldose reductase inhibitors. Adv. Exp. Med. Biol. (1988) 286:365–372.
   Google Scholar
• NARUSE K, NAKAMURA J, HAMADA Y et al.: Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes. Exp. Eye Res. (2000) 71:309–315.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Study Group. Arch. Ophthalmol (1990) 108:1234–1244.
   PubMed Web of Science ®Google Scholar
• PFEIFER MA, SCHUMER MP, GELBER DA: Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes (1997) 46\(Suppl. 2):582–589.
   Google Scholar
• VLASSARA H: Recent progress in advanced glycation end products and diabetic complications. Diabetes (1997) 46\(Suppl. 2):519–525.
   PubMedGoogle Scholar
• •Thorough overview of the biochemistry of AGE production and cell effects.
   Google Scholar
• BAYNES JW, THORPE SR: Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. (2000) 28: 1708–1716.
   Google Scholar
• KERN TS, TANG J, MIZUTANI M et al.: Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest. Ophthalmol Vis. ScL (2000) 41:3972–3978.
   PubMed Web of Science ®Google Scholar
• STITT A, GARDINER TA, ANDERSON NL et al.: The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes (2002) 51: 2826–2832.
   Google Scholar
• KOWLURU RA, TANG J, KERN TS: Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes (2001) 50: 1938–1942.
   Google Scholar
• TAKAHASHI T, UENO H, SHIBUYA M: VEGF activates protein kinase C-dependent, but ras-independent raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene (1999) 18:2221–2230.
   PubMed Web of Science ®Google Scholar
• SCIVITTARO V, GANZ MB, WEISS MF: AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am. .1.Physiol Renal Physiol (2000) 278:F676–F683.
   PubMed Web of Science ®Google Scholar
• KOYA D, KING GL: Protein kinase C activation and the development of diabetic complications. Diabetes (1998) 47:859–866.
   PubMed Web of Science ®Google Scholar
• KOWLURU RA, JIROUSEK MR, STRAMM L et al.: Abnormalities of retinal metabolism in diabetes or experimental galactosemia. Diabetes (1998) 47:464–469.
   PubMed Web of Science ®Google Scholar
• CHEN S, COHEN MP, ZIYADEH FN: Amadori-glycated albumin in diabetic nephropathy: pathophysiologic connections. Kidney Int. (2000) 58\(Suppl. 77):S40–S44.
   Google Scholar
• GARDNER TW, ANTONETTI DA, BARBER AJ, LANOUE KF, LEVISON SW: Diabetic retinopathy: more than meets the eye. Surv. Ophthalmol (2002) 47\(Suppl. 2):5253–5262.
   Google Scholar
• •Excellent review of recent observations regarding cellular anatomy contributing to the BRB.
   Google Scholar
• GILBERT RE, VRANES D, BERKA JL et al.: Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab. Invest. (1998) 78:1017–1027.
   PubMed Web of Science ®Google Scholar
• QAUM T, XU Q, JOUSSEN AM et al.: VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest. Ophthalmol Vis. Sci. (2001) 42:2408–2413.
   PubMed Web of Science ®Google Scholar
• POULAKI V, QIN W, JOUSSEN AM et al.: Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypcoda-inducible factor-1 alpha and VEGF. I Clin. Invert. (2002) 109:805–815.
   PubMed Web of Science ®Google Scholar
• AIELLO LP, BURSELL SE, CLERMONT A et al.: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes (1997) 46:1473–1480.
   PubMed Web of Science ®Google Scholar
• •First use of a selective PKC inhibitor to explore ocular physiology in an animal model of diabetes.
   Google Scholar
• ANTONETTI DA, BARBER AJ, KHIN S,LIETH E, TARBELL JM, GARDNER TW: Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes (1998) 47:1953–1959.
   PubMed Web of Science ®Google Scholar
• ANTONETTI DA, WOLPERT EB, DEMAIO L, HARHAJ NS, SCADUTO RC: Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. Neurochem. (2002) 80:667–677.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Angiogenesis: initiation and control. Ann. NY Acad. Sci. (1982) 401:212–227.
   PubMed Web of Science ®Google Scholar
• •A classic report of fundamental aspects of angiogenesis.
   Google Scholar
• SEBAG J: Pharmacologic vitreolysis. Retina (1998) 18:1–3.
   PubMed Web of Science ®Google Scholar
• KUPPERMAN B, THOMAS E, GRAUE M et al.: Clearance of vitreous hemorrhage after intravitreal administration of hyaluronidase: Preclinical pharmacology and clinical outcomes. ARVO Annual Meeting, Fort Lauderdale, FL, USA (2000):S347.
   Google Scholar
• GRAUE-WIECHERS F, DELGADILLO A, QUIROZ-MERCADO H et al.: Pharmacologic induction of a posterior vitreous detachment in human diabetic eyes treated with purified ovine hyaluronidase. American Academy of Ophthalmology Annual Meeting. Dallas, TX, USA (2000):99.
   PubMedGoogle Scholar
• SIMO R, LECUBE A, SEGURA RIVI, GARCIA ARUMI J, HERNANDEZ C: Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am. .1.Ophthalmol (2002) 134:376–382.
   PubMed Web of Science ®Google Scholar
• MILLER J, ADAMIS A, SHIMA D et al:Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol (1994) 145:574–584.
   PubMed Web of Science ®Google Scholar
• ADAMIS AP, SHIMA DT, TOLENTINO MJ et al.: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol (1996) 114:66–71.
   PubMed Web of Science ®Google Scholar
• •First use of a VEGF inhibitor to treat ocular angiogenesis.
   Google Scholar
• SCHLAEPPI JM, WOOD JM: Targetingvascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev (1999) 18:473–481.
   PubMed Web of Science ®Google Scholar
• AIELLO L, NORTHRUP J, KEYT B, TAKAGI H, IWAMOTO M: Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch. Ophthalmol (1995) 113:1538–1544.
   PubMed Web of Science ®Google Scholar
• ROBINSON GS, PIERCE EA, ROOK SL et al.: Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc. Nati Acad. Sci. USA (1996) 93:4851–4856.
   PubMed Web of Science ®Google Scholar
• •First use of antisense technology to treat intraocular angiogenesis.
   Google Scholar
• HONDA M, SAKAMOTO T, ISHIBASHI T, INOMATA H, UENO H: Experimental subretinal neovascularization is inhibited by adenovirus- mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Tiler. (2000) 7:978–985.
   Web of Science ®Google Scholar
• •First use of gene transfer technology to treat intraocular angiogenesis.
   Google Scholar
• NO AUTHORS LISTED: Preclinical and Phase IA clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. The Eyetech Study Group. Retina (2002) 22:143–152.
   PubMed Web of Science ®Google Scholar
• BREKKEN RA, OVERHOLSER JP, STASTNY VA et al.: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (kdr/flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. (2000) 60:5117–5124.
   PubMed Web of Science ®Google Scholar
• WEDGE SR, OGILVIE DJ, DUKES M et al.: Zd4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. (2000) 60:970–975.
   PubMed Web of Science ®Google Scholar
• KWAK N, OKAMOTO N, WOOD JM, CAMPOCHIARO PA: VEGF is major stimulator in model of choroidal neovascularization. Invest. Oplithalmol. Vis. Sci. (2000) 41:3158–3164.
   PubMed Web of Science ®Google Scholar
• CARTER SK: Clinical strategy for the development of angiogenesis inhibitors. Oncologist (2000) 5:51–54.
   PubMedGoogle Scholar
• •A good review of angiogenesis inhibition strategies in relation to tumour growth.
   Google Scholar
• SMITH LE, KOPCHICK JJ, CHEN W et al.: Essential role of growth hormone in ischemia-induced retinal neovascularization. Science (1997) 276:1706–1709.
   PubMed Web of Science ®Google Scholar
• •A particularly elegant report illustrating the interdependence of VEGF and IGF-1 in angiogenesis in the eye.
   Google Scholar
• SMITH LE, SHEN W, PERRUZZI C et al.: Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat. Med. (1999) 5:1390–1395.
   PubMed Web of Science ®Google Scholar
• PFEIFFER A, SPRANGER J, MEYER- SCHWICKERATH R, SCHATZ H:Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes (1997) 46\(Suppl. 2):526–530.
   Google Scholar
• DANIS RP, BINGAMAN DP, YANG Y, LEE W: Chronic upregulation of components of the IGF-1 system after a single intravitreal injection of hrIGF-1 in pigs. Invest. Opthalmol. Vis. Sci. (1996) 37(Suppl.):S203.
   Google Scholar
• YAMADA H, YAMADA E, ANDO A et al.: Platelet-derived growth factor-A-induced retinal gliosis protects against ischemic retinopathy. Am. .1.Pathol. (2000) 156:477–487.
   Google Scholar
• DANIS RP, BINGAMAN DP: Insulin-like growth factor-1 retinal microangiopathy in the pig eye. Ophthalmology (1997) 104(10):1661–1669.
   PubMed Web of Science ®Google Scholar
• IYER NV, KOTCH LE, AGANI F et al: Cellular and developmental control of 02 homeostasis by hypoxia- inducible factor 1 alpha. Genes Dev. (1998) 12:149–162.
   PubMed Web of Science ®Google Scholar
• KING GL, GOODMAN AD, BUZNEY S, MOSES A, KAHN CR: Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. Clin. Invert. (1985) 75:1028–1036.
   PubMed Web of Science ®Google Scholar
• MERIMEE T: A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes. N Engl. J. Med. (1978) 298(22):1217–1222.
   PubMed Web of Science ®Google Scholar
• KOHNER EM, HAMILTON AF, JOPLIN GF: Florid diabetic retinopathy and its response to treatment by photocoagulation or pituitary ablation. Diabetes (1976) 25:104–110.
   PubMed Web of Science ®Google Scholar
• CHEN T, MILLER TF, PRASAD P et al.:Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. .1 Clin. Pharmacol. (2000) 40:475–481.
   Google Scholar
• BOEHM BO, LANG GK, JEHLE PM, FELDMAN B, LANG GE: Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Dorm. Metab. Res. (2001) 33:300–306.
   PubMed Web of Science ®Google Scholar
• GRANT MB, MAMES RN FITZGERALD C et al.: The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diab. Care (2000) 23:504–509.
   PubMed Web of Science ®Google Scholar
• •The first clinical trial of a somatostatin analogue for PDR.
   Google Scholar
• STELLMACH V, CRAWFORD SE, ZHOU W, BOUCK N: Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc. Natl. Acad. Sci. USA (2001) 98:2122–2124.
   PubMed Web of Science ®Google Scholar
• MORI K, GEHLBACH P, ANDO A, MCVEY D, WEI L, CAMPOCHIARO PA: Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest. Oplithalmol. Vis. Sci. (2002) 43:2428–2434.
   PubMed Web of Science ®Google Scholar
• YAMAGASHI S, INAGAKI Y, AMANO S, OKAMOTO T, TAKEUCHI M, MAKITA Z: Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biocliem. Biophys. Res. Commun. (2002) 296:877–882.
   PubMed Web of Science ®Google Scholar
• OGATA N, TOMBRAN-TINK J, JO N, MRAZEK D, MATSUMURA M: Upregulation of pigment epithelium-derived factor after laser photocoagulation. Am. Oplithalmol. (2001) 132:427–429.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER M, BROOKS P, SHAFFER R et al.: Definition of two angiogenic pathways by distinct alpha v integrins. Science (1995) 270:1500–1502.
   PubMed Web of Science ®Google Scholar
• •An elegant study illustrating some important aspects of intracellular signal transduction via integrins.
   Google Scholar
• LUNA J, TOBE T, MOUSA SA, REILLY TM, CAMPOCHIARO PA: Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. Lab. Invest. (1996) 75:563–573.
   PubMed Web of Science ®Google Scholar
• HAMMES HP, BROWNLEE M, JONCZYK A, SUTTER A, PREISSNER KT: Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med. (1996) 2:529–533.
   PubMed Web of Science ®Google Scholar
• NELSON AR, FINGLETON B, ROTHENBERG ML, MATRISIAN LM: Matrix metalloproteinases: biologic activity and clinical implications. Clin. Oncol. (2000) 18:1135–1149.
   Web of Science ®Google Scholar
• ••In-depth review of this class ofantiangiogenic agents.
   Google Scholar
• ABU EL-ASRAR AM, DRALANDS L, VECKENEER M et al.: Gelatinase B in proliferative vitreoretinal disorders. Am. Oplithalmol. (1998) 125:844–851.
   PubMed Web of Science ®Google Scholar
• DAS A, MCGUIRE PG, ERIQAT C et al: Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest. Ophthalmol Vis. Sci. (1999) 40:809–813.
   PubMed Web of Science ®Google Scholar
• KOSANO H, OKANO T, KATSURA Y et al.: ProMMP-9 (92 kda gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci. (1999) 64:2307–2315.
   PubMed Web of Science ®Google Scholar
• DAHL-JORGENSEN K: Diabetic microangiopathy. Acta Paediatr. Sapp]. (1998) 425:31–34.
   Google Scholar
• GARCIA C, BARTSCH D, RIVERO M et al.: Efficacy of prinomastat® (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. CLIFF. Eye Res. (2002) 24:33–38.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J, INGBER D: Angiostatic steroids. Ann. Stag. (1987) 206:374–382.
   Google Scholar
• •A classic report.
   Google Scholar
• INGBER D, MADRI J, FOLKMAN J: A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology (1986) 119:1768–1775.
   PubMed Web of Science ®Google Scholar
• DANIS RP, BINGAMAN DP, YANG Y, LADD L: Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology (1996) 103:2099–2104.
   PubMed Web of Science ®Google Scholar
• ROTSCHILD T, NANDGAONKAR BN, YU K, HIGGINS RD: Dexamethasone reduces oxygen induced retinopathy in a mouse model. Pediatr. Res. (1999) 46:94–100.
   PubMed Web of Science ®Google Scholar
• CIULLA TA, CRISWELL MH, DANIS RP, HILL TE: Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch. Ophthalmol (2001) 119:399–404.
   PubMed Web of Science ®Google Scholar
• MARTIDIS A, MILLER DG, CIULLA TA, DANIS RP, MOORTHY RS: Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. Ocul. Pharmacol Ther. (1999) 15:425–428.
   PubMed Web of Science ®Google Scholar
• DANIS RP, CIULLA TA, PRATT LM, ANLIKER W: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina (2000) 20:244–250.
   PubMed Web of Science ®Google Scholar
• MARTIDIS A, NELSON ML, BAKER B et al.: Intravitreal triamcinolone for refractory diabetic macular edema. Vitreous Society Annual Meeting, San Francisco, CA, USA (2002):144–145.
   Google Scholar
• PEARSON P, ABOU-JAOUDE E, SMITH T, ASHTON P: A Phase I evaluation of sustained delivery fluocinolone in the treatment of diabetic macular edema. American Academy of Ophthalmology Annual Meeting, Dallas, TX, USA (2000):99.
   Google Scholar
• TERUO S, INOGUCHI T, SPORTSMAN JR et al.: Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am. Physiol (1993) 265:E783–E793.
   PubMed Web of Science ®Google Scholar
• TRANQUE PA, CALLE R, NAFTOLIN F, ROBBINS R: Involvement of protein kinase-C in the mitogenic effect of insulin-like growth factor-1 on rat astrocytes. Endocrinology (1992) 131: 1948–1954.
   Google Scholar
• INOGUCHI T, BATTAN R, HANDLER E et al: Preferential elevation of protein kinase C beta II isoform and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc. Nati Acad. Sci. USA (1992) 88:11059–11068.
   Google Scholar
• SEO MS, KWAK N, OZAKI H et al: Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am. Pathol (1999) 154:1743–1753.
   PubMed Web of Science ®Google Scholar
• JIROUSEK MR, GILLIG JR, GONZALEZ CM et al: S-13-Rdimethylamino)methy11-10,11,14,15-tetrahydro-4,9:16,21 -dimetheno-1 h, 13 h-dibenzo [e,k]pyrrolo [3,4- h] [1,4,13]oxadiazacyclohexadecene-1,3(2h)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. Med. Chem. (1996) 39:2664–2671.
   Web of Science ®Google Scholar
• •Detailed report of a highly selective PKC beta II inhibitor.
   Google Scholar
• DANIS RP, BINGAMAN DP, JIROUSEK M, YANG Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531.Invest. Ophthalmol Vis. Sci. (1998) 39:171–179.
   PubMed Web of Science ®Google Scholar
• HAYASHI A, KIM H, DE JUAN E JR: Alterations in protein tyrosine kinase pathways following retinal vein occlusion in the rat. Curr: Eye Res. (1999) 18:231–239.
   PubMed Web of Science ®Google Scholar
• DANIS R, CRISWEL M, ORGE F, MONIA B, HENRYS: Angioinhibitory action of intravitreous anti-raf-1 kinase antisense oligonucleotide in the pig BVO model. Carr. Eye Res. (2003) (in press).
   PubMedGoogle Scholar